MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
0.877
+0.004 (0.40%)
At close: Apr 28, 2026, 4:00 PM EDT
0.895
+0.018 (2.00%)
After-hours: Apr 28, 2026, 7:27 PM EDT

Company Description

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.

The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.

The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing.

MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

MaxCyte, Inc.
MaxCyte logo
Country United States
Founded 1999
IPO Date Jul 30, 2021
Industry Medical Devices
Sector Healthcare
Employees 91
CEO Maher Masoud

Contact Details

Address:
9713 Key West Avenue, Suite 400
Rockville, Maryland 20850
United States
Phone 301 944 1700
Website maxcyte.com

Stock Details

Ticker Symbol MXCT
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $13.00
CIK Code 0001287098
CUSIP Number 57777K106
ISIN Number US57777K1060
Employer ID 52-2210438
SIC Code 8731

Key Executives

Name Position
Maher Masoud President, Chief Executive Officer and Executive Director
Parmeet Ahuja Chief Financial Officer
Jay Gelfman Senior Vice President of Operations
Jack Horgan Senior Vice President of Corporate Development
Ana-Paula Martins Fernandes Senior Vice President of Global Sales
Jill Mayer Senior Vice President of Human Resources

Latest SEC Filings

Date Type Title
Apr 15, 2026 S-8 Securities to be offered to employees in employee benefit plans
Apr 10, 2026 SCHEDULE 13G/A Filing
Mar 27, 2026 8-K Current Report
Mar 27, 2026 SCHEDULE 13G/A Filing
Mar 25, 2026 10-K Annual Report
Mar 24, 2026 8-K Current Report
Mar 20, 2026 8-K Current Report
Feb 17, 2026 SCHEDULE 13G/A Filing
Feb 5, 2026 SCHEDULE 13G Filing
Jan 21, 2026 SCHEDULE 13G/A Filing